JP2026503201A5 - - Google Patents

Info

Publication number
JP2026503201A5
JP2026503201A5 JP2025529815A JP2025529815A JP2026503201A5 JP 2026503201 A5 JP2026503201 A5 JP 2026503201A5 JP 2025529815 A JP2025529815 A JP 2025529815A JP 2025529815 A JP2025529815 A JP 2025529815A JP 2026503201 A5 JP2026503201 A5 JP 2026503201A5
Authority
JP
Japan
Prior art keywords
peg
optionally substituted
compound
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025529815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026503201A (ja
Filing date
Publication date
Priority claimed from CN202310009545.8A external-priority patent/CN115947672B/zh
Application filed filed Critical
Publication of JP2026503201A publication Critical patent/JP2026503201A/ja
Publication of JP2026503201A5 publication Critical patent/JP2026503201A5/ja
Pending legal-status Critical Current

Links

JP2025529815A 2023-01-04 2023-03-29 薬物を送達するための化合物、リポソーム及び薬物担体 Pending JP2026503201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202310009545.8A CN115947672B (zh) 2023-01-04 2023-01-04 用于递送药物的化合物、脂质体及药物载体
CN202310009545.8 2023-01-04
PCT/CN2023/084757 WO2024146016A1 (zh) 2023-01-04 2023-03-29 用于递送药物的化合物、脂质体及药物载体

Publications (2)

Publication Number Publication Date
JP2026503201A JP2026503201A (ja) 2026-01-28
JP2026503201A5 true JP2026503201A5 (enExample) 2026-04-07

Family

ID=87285824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025529815A Pending JP2026503201A (ja) 2023-01-04 2023-03-29 薬物を送達するための化合物、リポソーム及び薬物担体

Country Status (7)

Country Link
US (1) US20250134813A1 (enExample)
EP (1) EP4647421A1 (enExample)
JP (1) JP2026503201A (enExample)
KR (1) KR20250152061A (enExample)
CN (1) CN115947672B (enExample)
AU (1) AU2023420649A1 (enExample)
WO (1) WO2024146016A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003403D0 (en) 2020-03-09 2020-04-22 Oribiotech Ltd A system for cell processing
CN120677142A (zh) * 2022-11-02 2025-09-19 益杰立科(上海)生物科技有限公司 一种用于递送系统的化合物及其用途
CN115947672B (zh) * 2023-01-04 2024-02-27 成都威斯津生物医药科技有限公司 用于递送药物的化合物、脂质体及药物载体
CN116768744A (zh) * 2023-08-17 2023-09-19 中节能万润股份有限公司 一种脂质化合物、脂质纳米颗粒组合物和应用
CN117088825A (zh) * 2023-10-12 2023-11-21 成都威斯津生物医药科技有限公司 一种可离子化脂质、含该可离子化脂质的药物组合物及其用途
WO2026019691A1 (en) * 2024-07-15 2026-01-22 The Board Of Trustees Of The Leland Stanford Junior University Discrete immolative guanidinium transporters and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588339B2 (ja) * 1992-06-02 1997-03-05 花王株式会社 新規ジアミノジエステル及びその製造法
US5614170A (en) * 1994-11-30 1997-03-25 Hemagen/Pfc Paramagnetic complexes of N-alkyl-N-hydroxylamides of organic acids and emulsions containing same for magnetic resonance imaging (MRI)
DE19637043A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
US10167253B2 (en) * 2015-06-24 2019-01-01 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
EP3842412B1 (en) * 2018-08-21 2024-04-24 Kabushiki Kaisha Toshiba Biodegradable lipids for delivery of active compounds into tumor cells comprising two or more tertiary amino groups
WO2020061367A1 (en) * 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
KR102924173B1 (ko) * 2020-04-09 2026-02-06 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 나노입자 조성물
CN115947672B (zh) * 2023-01-04 2024-02-27 成都威斯津生物医药科技有限公司 用于递送药物的化合物、脂质体及药物载体

Similar Documents

Publication Publication Date Title
JP4842821B2 (ja) ポリエチレングリコール修飾脂質化合物およびその使用
EP1750673B1 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
JP2020510072A5 (enExample)
Jadhav et al. Novel vesicular system: an overview
JP2022502451A5 (enExample)
HRP20220156T1 (hr) Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
JP2018532721A5 (enExample)
EP2608785B1 (en) Lipomacrocycles and uses thereof
JPH08510748A (ja) リポソームが誘発する生理的副作用の低減
JP2024527940A5 (enExample)
JP7832717B2 (ja) 硫化物を含むイオン化可能な脂質、及びこれを含む脂質ナノ粒子
US12582610B2 (en) Lipid-polymer compositions and methods of use
CN101670112A (zh) 一种稳定的白蛋白脂质载药系统及其制备方法
KR102911928B1 (ko) 신규 이온화 가능한 지질 및 이를 포함하는 지질나노입자
JP2002531534A (ja) タモキシフェン含有リポソーム系腫瘍治療剤
EP4642787A2 (en) Modular lipid compounds and two- to three-component lipid nanoparticle compositions
WO2024019770A1 (en) Methods of making ionizable lipids and lipid nanoparticles for mrna delivery
WO2025172284A1 (en) Lipids for nanoparticle delivery platform
WO2025171440A1 (en) Nanoparticles
WO2025081002A1 (en) Ionizable lipids for the delivery of nucleic acids
WO2024035932A1 (en) Lyophilized nanoparticle compositions and methods of use thereof
JP2007210953A (ja) pH応答性分子集合体
TW202404568A (zh) 用於藥物遞送之化合物及組合物
WO2025017370A2 (en) Delivery system comprising lipid or polymeric nanoparticles comprising thyroid hormones
NZ820531B2 (en) Long-acting spleen-targeting cationic lipid compound comprising benzene ring structure, composition comprising same, and use thereof